Creative Planning Inhibrx, Inc. Transaction History

Creative Planning

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$32.76 - $39.56 $6,420 - $7,753	196 Added 1.48%	13,466 $470,000
Q4 2023 Feb 14, 2024	BUY	$14.5 - $38.0 $15,805 - $41,420	1,090 Added 8.95%	13,270 $504,000
Q3 2023 Nov 16, 2023	BUY	$15.75 - $26.31 $2,835 - $4,735	180 Added 1.5%	12,180 $223,000
Q1 2023 May 15, 2023	SELL	$18.45 - $27.14 $5,129 - $7,544	-278 Reduced 2.26%	12,000 $226,000
Q4 2022 Feb 10, 2023	BUY	$20.18 - $33.33 $5,610 - $9,265	278 Added 2.32%	12,278 $302,000
Q1 2021 Apr 30, 2021	BUY	$16.27 - $41.26 $195,240 - $495,120	12,000 New	12,000 $241,000

25.3K

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $617M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

Stay updated on Creative Planning with notifications on news.